Transient Ischemic Attack
Conditions
Interventions
None listed
Sponsors
Osaka Metropolitan University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Studies were deemed eligible for inclusion if they satisfied all of the following criteria: (1) they were double-blind, placebo-controlled randomized clinical trials; (2) they enrolled adults aged 18 years or older with recent non-cardioembolic ischemic stroke or high-risk TIA; and (3) they evaluated an oral or injectable FXIa inhibitor administered alongside background antiplatelet therapy.
Exclusion criteria
Exclusion criteria: . Studies were excluded if they enrolled patients exclusively for primary prevention, were limited to cardioembolic stroke or atrial fibrillation populations, or employed a nonrandomized design. Additionally, observational studies, case reports, case series, editorials, reviews, and conference abstracts without sufficient outcome data were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy outcome was recurrent ischemic stroke | — |
Secondary
| Measure | Time frame |
|---|---|
| The primary safety outcome was major bleeding. | — |
Countries
Japan,Asia(except Japan),North America,South America,Australia,Europe,Africa
Contacts
Public ContactToshiyuki Kawashima
Osaka Metropolitan University Hospital Department of Neurosurgery
Outcome results
None listed